The enrollment criteria included diagnosis of stage IB (≥4 cm) to IIIA (AJCC 7th Edition) NSCLC, ECOG status of 0–1, no prior anticancer therapy, and pre-treatment tissue available for analysis of PDL1 expression. Here, CD274 is linked to non-small cell lung carcinoma.